Hematologic Diseases D006402

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases

Description

Disorders of the blood and blood forming tissues.   MeSH

Subtype Terms (18)

Anemia
310 drugs (193 approved, 117 experimental)

Blood Coagulation Disorders
29 drugs (22 approved, 7 experimental)

Blood Platelet Disorders
46 drugs (32 approved, 14 experimental)

Blood Protein Disorders
14 drugs (12 approved, 2 experimental)

Bone Marrow Diseases
49 drugs (37 approved, 12 experimental)

Erythroblastosis, Fetal
4 drugs (3 approved, 1 experimental)

Hematologic Neoplasms
299 drugs (142 approved, 157 experimental)

Hemoglobinopathies
39 drugs (25 approved, 14 experimental)

Hemorrhagic Disorders
13 drugs (6 approved, 7 experimental)

Leukocyte Disorders
3 drugs (2 approved, 1 experimental)

Methemoglobinemia
6 drugs (5 approved, 1 experimental)

Pancytopenia
10 drugs (7 approved, 3 experimental)

Polycythemia
12 drugs (10 approved, 2 experimental)

Pregnancy Complications, Hematologic
2 approved drugs

Preleukemia
10 drugs (7 approved, 3 experimental)

Sulfhemoglobinemia
 

Thrombophilia
12 drugs (8 approved, 4 experimental)

Transfusion Reaction
11 drugs (7 approved, 4 experimental)


Approved Indicated Drugs (2)


Organization Involved with Phase 3 Indications (62)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.